Studienregister

Studienregister der Deutschen Gesellschaft für Urologie e.V.

  • Benigne Prostatahyperplasie (Beschreibung)
  • Erektile Dysfunktion
  • Harnblasenkarzinom (Beschreibung)
  • Harninkontinenz
  • Hodentumor (Beschreibung)
  • Nierenzellkarzinom (Beschreibung)
  • Prostatakarzinom (Beschreibung)
    • ALSYMPCA: A double-blind, randomised, multiple dose, phase III, multicentre study of AlpharadinTM in the treatment of patients with symptomatic hormone refractory prostate cancer with skeletal metastases
    • AP 52/08 - Enthuse M0: A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD 4054 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients
    • AP 55/09 - SEAL:
    • AP 59/10 - OGX-011-11: A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination with Custirsen (OGX-011) in Men with Metastatic Castrate Resistant Prostate Cancer
    • COPCa: Coping with Prostate Cancer
    • g-Rampp: Multicentric, Prospective, Randomized Controlled Trial Comparing Radical Prostatectomy Plus Neoadjuvant Hormones With Androgen Deprivation Therapy Alone in the Management of Men With Pauci-metastatic Prostate Cancer
    • HAROW-Studie: Therapy situation of men with newly diagnosed locally confined prostate cancer in Germany - a prospective evaluation study
    • MATuRITY: Management of Advanced prostate cancer in senior adults: a prospective international registry
    • QoLiTax:
    • @-Registry-Studie: not available
    • SCOPE: Non-interventional study to evaluate the influence of the sequence in which Cabazitaxel is applied on the outcome of patients with metastatic castration-resistant prostate cancer treated with Cabazitaxel (SCOPE)
    • SEAL 2: n.a. - german study
    • Soma-47-Studie:
    • SP005 VIABLE: A Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st LineChemotherapy
    • TRITON 2_CO-338-052: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency
    • TRITON 3_CO-338-063: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician’s Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency
  • Überaktive Blase (Beschreibung)
  • Urothelkarzinom (Beschreibung)

nach oben